Taguchi, Kazuaki

写真a

Affiliation

Faculty of Pharmacy, Department of Pharmacy 薬効解析学講座 (Shiba-Kyoritsu)

Position

Associate Professor

Career 【 Display / hide

  • 2010.04
    -
    2011.03

    日本学術振興会特別研究員

  • 2011.04
    -
    2013.03

    熊本大学医学部附属病院, 薬剤部, 薬剤師

  • 2013.04
    -
    2017.03

    崇城大学 , 薬学部, 助教

  • 2018.04
    -
    2021.03

    慶應義塾大学, 薬学部, 専任講師

  • 2021.04
    -
    Present

    慶應義塾大学, 薬学部, 准教授

Academic Background 【 Display / hide

  • 2006.03

    Kumamoto University, 薬学部

    University, Graduated

  • 2008.03

    Kumamoto University

    Graduate School, Completed, Master's course

  • 2011.03

    Kumamoto University

    Graduate School, Completed, Doctoral course

Academic Degrees 【 Display / hide

  • 博士 (薬学), 熊本大学, 2011.03

Licenses and Qualifications 【 Display / hide

  • 薬剤師, 2006.04

 

Books 【 Display / hide

  • Carbon monoxide-bound Hemoglobin-Vesicles: Current facts and potential medical applications.

    Taguchi K, Matsumoto K, Sakai H, Maruyama T, Otagiri M, World Scientific Publishing Co. Pte. Ltd., 2021.12

    Scope: Chapter 6.10.,  Contact page: 849-865

  • DDS先端技術の製剤への応用開発

    宗慶太郎, 田口和明, 技術情報協会, 2017

    Scope: 第6章6節 pp. 360-8

  • Human Serum Albumin (HSA): Functional Structure, Synthesis and Therapeutic Uses

    Taguchi K, Chuang VT, Yamasaki K, Otagiri M., Nova Science Publishers, Inc., 2015

    Scope: Chapter 4, pp. 69-89

  • HUMAN SERUM ALBUMIN

    Taguchi K, Chuang VT, Otagiri M., 2013

    Scope: Chapter 20, pp. 401-15

  • Acute Phase Proteins

    Taguchi K, Nishi K, Chuang VT, Maruyama T, Otagiri M., Intech, 2013

    Scope: Chapter 6, pp.139-62

Papers 【 Display / hide

  • Oxidized liposomal artificial red blood cells rescue azide-poisoned mice from lethal toxidrome by recovering cytochrome c oxidase activity

    Suzuki Y., Taguchi K., Hanyu S., Kure T., Enoki Y., Otagiri M., Sakai H., Matsumoto K.

    Journal of Drug Delivery Science and Technology (Journal of Drug Delivery Science and Technology)  71 2022.05

    ISSN  17732247

     View Summary

    Exposure to azide compounds causes inhibition of cytochrome c oxidase in the mitochondria, leading to acute lethal poisoning. Although urgent pharmaceutical intervention is required for rescue from azide poisoning, no antidote exists worldwide. We hypothesized that methemoglobin (metHb) can be a promising material as an antidote for azide poisoning because metHb can strongly bind to azide. However, metHb administration is not feasible owing to in vivo instability and toxicity. We aimed to develop a feasible metHb-based antidote for azide poisoning, in which the inner hemoglobin of liposomal artificial red blood cells is oxidized by mixing with sodium nitrite. From the stopped-flow spectrophotometry analysis, as-prepared oxidized liposomal artificial red blood cells, which encapsulated metHb into the liposome (metHb@Lipo), the binding affinity of metHb@Lipo to azide was comparable to that of bare metHb. In addition, detoxification by metHb@Lipo increased the survival rate in lethal azide-poisoned model mice with recovery of cytochrome c oxidase activity, leading to the amelioration of acidosis and tissue oxidation. Furthermore, metHb@Lipo detoxification functioned even after 1 year of storage in a ready-to-use formulation. These results indicate that oxidized liposomal artificial red blood cells are a potent antidote for azide poisoning with favorable properties for use in critical care medicine.

  • Impact of rifampicin on the pharmacokinetics of clarithromycin and 14-hydroxy clarithromycin in patients with multidrug combination therapy for pulmonary Mycobacterium avium complex infection.

    Iketani O, Komeya A, Enoki Y, Taguchi K, Uno S, Uwamino Y, Matsumoto K, Kizu J, Hasegawa N

    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy (Journal of Infection and Chemotherapy)  28 ( 1 ) 61 - 66 2022.01

    Research paper (scientific journal), Accepted,  ISSN  1341-321X

     View Summary

    Introduction: Clarithromycin (CAM), ethambutol (EB), and rifampicin (RFP) combination therapy is used to treat pulmonary Mycobacterium avium complex (MAC) infection; however, serum CAM concentration decreases due to RFP-mediated induction of CYP3A activity. Therefore, we investigated the pharmacokinetics of CAM, 14-hydroxy clarithromycin (14-OH CAM), EB, and RFP in patients receiving this three-drug combination therapy. Methods: CAM monotherapy was started, EB was added 2 weeks later, and RFP was added 2 weeks after that. Serum CAM, 14-OH CAM, EB, and RFP concentrations were measured before and at 2, 4, 6, and 12 or 24 h after administration on days 14, 28, and 42, and pharmacokinetic parameters were calculated. Results: Median area under the curve (AUC) of CAM decreased by 92.1% from 0 to 12 h after concomitant administration of RFP compared with CAM monotherapy [1.7 (interquartile range [IQR], 1.4–1.8) μg·h/mL vs. 21.5 (IQR, 17.7–32.3) μg·h/mL, respectively]. In contrast, median AUC of 14-OH CAM was not significantly different between concomitant administration of RFP [9.1 (IQR, 7.9–10.9) μg·h/mL] and CAM monotherapy [8.2 (IQR, 6.3–9.3) μg·h/mL]. AUCs of CAM and 14-OH CAM did not change in CAM+EB combination therapy. Conclusions: When RFP is combined with CAM in the treatment of pulmonary MAC infection, the blood concentration of CAM significantly decreased and that of the active metabolite 14-OH CAM increased, but not significantly. Our results suggest that combination therapy with CAM and RFP needs to be reconsidered and may require dose modification in the treatment of pulmonary MAC infection.

  • Liposomal artificial red blood cell-based carbon monoxide donor is a potent renoprotectant against cisplatin-induced acute kidney injury

    Taguchi K., Suzuki Y., Tsutsuura M., Hiraoka K., Watabe Y., Enoki Y., Otagiri M., Sakai H., Matsumoto K.

    Pharmaceutics (Pharmaceutics)  14 ( 1 )  2022.01

    Research paper (scientific journal), Accepted

     View Summary

    Cisplatin (CDDP) is an essential anti-tumor agent for chemotherapeutic regimens against various types of cancer. However, the progression of nephrotoxicity, which is the main adverse effect of CDDP, leads to discontinuation of CDDP chemotherapy. Therefore, development of a renopro-tectant against CDDP-induced nephrotoxicity is crucial. Here, the potential of a carbon monoxide (CO)-loaded hemoglobin-vesicle (CO-HbV) as a renoprotectant for CDDP-induced nephrotoxicity was evaluated for its renoprotective effects against CDDP-induced nephrotoxicity, inhibitory effects on the anti-tumor activity of CDDP, and anti-tumor activity. In healthy mice, after pretreatment with either saline, HbV, or CO-HbV prior to CDDP administration, only the CO-HbV pretreatment group ameliorated the progression of CDDP-induced nephrotoxicity by suppressing apoptosis via caspase-3. In experiments using B16-F10 melanoma cells, the half-maximal inhibitory concentration of CDDP decreased with co-incubation with CO-HbV, owing to the anti-tumor activity of CO. CO-HbV pretreatment had no impact on the anti-tumor activity of CDDP in B16-F10 melanoma cell-bearing mice, which was consistent with the results of the cell experiment. Furthermore, CO-HbV pretreatment improved body growth and survival rates. In conclusion, CO-HbV pretreatment is a potent renoprotectant for CDDP-induced nephrotoxicity, allowing treatment with CDDP to be conducted without failure of cancer treatment.

  • Long-term pharmaceutical stability of liposome-encapsulated methemoglobin as an antidote for cyanide poisoning

    Suzuki Y., Taguchi K., Kure T., Enoki Y., Otagiri M., Sakai H., Matsumoto K.

    International Journal of Pharmaceutics (International Journal of Pharmaceutics)  610   121260 2021.12

    Research paper (scientific journal), Accepted,  ISSN  03785173

     View Summary

    Liposome-encapsulated methemoglobin (metHb@Lipo) has been developed as a novel antidote for cyanide poisoning. Antidotes for lethal acute poisoning should be capable of being easily stored as ready-to-use formulations without temperature restrictions. Here, we investigated the pharmaceutical stability of the metHb@Lipo suspension after one-year storage as a ready-to-use formulation at 4 °C, room temperature (23–28 °C) and 37 °C. The liposomal integrity of metHb@Lipo was observed after one year of storage at all storage temperatures with no physicochemical change or methemoglobin leakage outside the liposome. Furthermore, the encapsulated methemoglobin remained intact without aggregation, fragmentation, denaturation, or dissociation of heme. Fresh and stored metHb@Lipo were equivalent in their binding affinity against cyanide. Moreover, all one-year stored metHb@Lipo suspensions improved the mortality rates of lethal cyanide poisoning mice comparable to fresh metHb@Lipo suspension. Additionally, all stored metHb@Lipo suspensions preserved high biocompatibility, including blood compatibility and the lack of organ toxicity. In conclusion, the metHb@Lipo suspension was a pharmaceutically stable antidote for cyanide poisoning for at least one year without any temperature restrictions.

  • Incidence of elevated creatine phosphokinase between daptomycin alone and concomitant daptomycin and statins: A systematic review and meta-analysis.

    Samura M, Takada K, Hirose N, Kurata T, Nagumo F, Koshioka S, Ishii J, Uchida M, Inoue J, Enoki Y, Taguchi K, Tanikawa K, Matsumoto K

    British journal of clinical pharmacology 88 ( 5 ) 1985 - 1998 2021.12

    Research paper (scientific journal), Accepted,  ISSN  0306-5251

display all >>

Papers, etc., Registered in KOARA 【 Display / hide

Reviews, Commentaries, etc. 【 Display / hide

  • The charm of protein for drug development

    Ishima Y., Taguchi K.

    Yakugaku Zasshi (Yakugaku Zasshi)  140 ( 2 ) 139 - 140 2020.02

    ISSN  00316903

  • 細胞型人工赤血球の動態特性解析に基づく安全性評価と医療ガスデリバリーへの応用

    田口 和明

    YAKUGAKU ZASSHI 138   1381 - 1389 2018

    Article, review, commentary, editorial, etc. (scientific journal), Single Work

  • The use of Hemoglobin vesicles for delivering medicinal gas for the treatment of intractable disorders.

    Taguchi K, Yamasaki K, Sakai H, Maruyama T, Otagiri M.

    J Pharm Sci. 106 ( 9 ) 2392 - 2400 2017

    Article, review, commentary, editorial, etc. (scientific journal), Joint Work

  • Comparison of the pharmacokinetic properties of hemoglobin-based oxygen carriers.

    Taguchi K, Yamasaki K, Maruyama T, Otagiri M.

    J Funct Biomater. 8 ( 1 ) E11 2017

    Article, review, commentary, editorial, etc. (scientific journal), Joint Work

  • Potential use of biological proteins for liver failure therapy.

    Taguchi K, Yamasaki K, Seo H, Otagiri M.

    Pharmaceutics. 7 ( 3 ) 255 - 274 2015

    Article, review, commentary, editorial, etc. (scientific journal), Joint Work

display all >>

Presentations 【 Display / hide

  • Research on pharmacokinetic analysis and safety evaluation for clinical development of artificial blood.

    Kazuaki Taguchi

    日本薬物動態学会第36年会, 

    2021.11

    Oral presentation (invited, special)

  • ヘモグロビンを用いた一酸化炭素製剤の開発

    田口和明,小田切優樹,松元一明

    第28回日本血液代替物学会年次大会, 

    2021.10

    Symposium, workshop panel (nominated)

  • 健康セミナー参加者を対象としたセルフメディケーション税制に関する実態調査

    田口 和明、榎木 裕紀、有賀 聡美、榊原 幹夫、堀 里子、山浦 克典、松元 一明

    第31回日本医療薬学会年会, 

    2021.10

    Poster presentation

  • 赤血球バイオミメティックによる生理活性ガス送達戦略と難治性疾患治療への展開

    田口 和明

    第37回日本DDS学会学術集会, 

    2021.06

    Oral presentation (invited, special)

  • Medical application of hemoglobin-based artificial blood by delivering carbon monoxide

    Kazuaki Taguchi, Toru Maruyama, Kazuaki Matsumoto, Hiromi Sakai, Masaki Otagiri

    第85回日本循環器学会学術集会, 

    2021.03

    Symposium, workshop panel (nominated)

display all >>

Research Projects of Competitive Funds, etc. 【 Display / hide

  • ヘモグロビン内封リポソームを用いたシアン化物中毒解毒剤の開発

    2019.04
    -
    2021.03

    橋渡し研究戦略的推進プログラム シーズA, Other, Principal investigator

  • 震災特有疾患に対する一酸化炭素結合型ヘモグロビン小胞体の医薬品としての有用性評価

    2017.04
    -
    2020.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), Principal investigator

  • 一酸化炭素結合ヘモグロビン小胞体の多機能型蘇生剤としての有用性評価

    2014.04
    -
    2017.03

    科学研究費補助金・若手研究B, Research grant, Principal investigator

  • 一酸化炭素結合型ヘモグロビン小胞体の特発性肺線維症新規治療薬としての有用性評価

    2012.04
    -
    2014.03

    科学研究費補助金・若手研究B, Research grant, Principal investigator

Intellectual Property Rights, etc. 【 Display / hide

  • メトヘモグロビン小胞体を有効成分として含む医薬およびその使用

    Date applied: 特願2020-144044,PCT/JP2021/ 31458  2020.08 

    Patent, Joint

  • 横紋筋融解症治療剤

    Date issued: 特許第6523842号  2019.05

    Patent, Joint

Awards 【 Display / hide

  • 熊本大学学長賞

    2011.03

  • 日本薬学会九州支部学術奨励賞

    2017.12

  • 日本薬学会奨励賞

    2020.03

    Type of Award: Award from Japanese society, conference, symposium, etc.

  • 日本DDS学会奨励賞 (臨床)

    2021.06, 日本DDS学会

    Type of Award: Award from Japanese society, conference, symposium, etc.

  • 日本薬物動態学会奨励賞

    2021.11, 日本薬物動態学会

    Type of Award: International academic award (Japan or overseas)

 

Courses Taught 【 Display / hide

  • STUDY OF MAJOR FIELD (PHARMACODYNAMICS)

    2022

  • SEMINAR (PHARMACODYNAMICS)

    2022

  • RESEARCH FOR BACHELOR'S THESIS 1

    2022

  • PRIOR LEARNING FOR CLINICAL PRACTICE 1

    2022

  • PRE-CLINICAL TRAINING FOR HOSPITAL & COMMUNITY PHARMACY

    2022

display all >>